ArticleBMC research notes2026
Feasibility of serial cfDNA measurement after perflubutane microbubble (Sonazoid
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating cell-free DNA (cfDNA) is a promising liquid biopsy biomarker in pancreatic ductal adenocarcinoma (PDAC), but clinical sensitivity remains limited, particularly in localized disease. Experimental studies suggest that transient modulation of hepatic clearance may increase recoverable cfDNA. Perflubutane microbubbles (Sonazoid
methodsThis single-center prospective pilot study enrolled patients with resectable or borderline-resectable PDAC scheduled for curative-intent surgery. Perflubutane microbubbles (Sonazoid
resultsFive patients were enrolled, and all completed the full protocol without deviations. Of these, four had resectable disease and one had borderline-resectable disease. Clinical stage at presentation ranged from IB to IIIA. Serial blood collection, plasma processing, cfDNA extraction, and fluorometric quantification were successfully performed for all 25 planned samples. Baseline cfDNA concentrations ranged from 0.564 to 0.946 ng/µL. Four patients showed a decrease in cfDNA concentration at 5 min followed by relative stability through 60 min, whereas one patient demonstrated a transient greater-than-two-fold increase at 5 min, followed by persistently higher-than-baseline values through 60 min. At the cohort level, no consistent increase in cfDNA concentration was observed. No adverse events related to Sonazoid
conclusionsSerial peri-procedural cfDNA measurement using standardized sampling and fluorometric quantification was feasible and safe in patients with resectable or borderline-resectable PDAC. Administration of perflubutane microbubbles at standard diagnostic doses did not induce a uniform or sustained increase in circulating cfDNA concentrations in this pilot cohort. These findings provide feasibility data and may inform the design of future studies evaluating cfDNA dynamics after clearance-modulating interventions in PDAC. Trial Registration This study is registered in the Japan Registry of Clinical Trials (jRCT) under the identifier jRCTs071240095, registered on January 10, 2025. Registration details are available at: https://jrct.mhlw.go.jp/latest-detail/jRCTs071240095.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.